Champions Oncology, Inc.

Champions Oncology, Inc. is a technology-enabled research organization that creates technology solutions for drug discovery and development. The company's research center operates in both regulatory and non-regulatory environments, utilizing a comprehensive set of computational and experimental research platforms. Its pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. A core component of these platforms is the company's proprietary bank of Patient Derived Xenograft (PDX) models. This bank of PDX models is used in advanced in vivo and ex vivo pharmacology platforms to provide insights into therapeutic programs. Champions Oncology currently has approximately 1,500 PDX Models in its TumorBank, which are believed to reflect the characteristics of patients in clinical trials (late stage, pretreated, and metastatic). These tumors are implanted and expanded in mice for future studies and characterization. Additional analytical and pharmacology experimental platforms are available to augment information from studies. The PDX bank is highly characterized at the molecular, phenotypic, and pharmacological levels, contributing a differentiated layer of data to the company's large oncology dataset, referred to as the "Datacenter." The Datacenter combines the company's proprietary dataset with other large publicly available datasets. This dataset currently includes approximately 3,500 molecular datasets (genomics, transcriptomics, proteomics, phosphor-proteomics), approximately 3,000 clinical drug responses, approximately 3,500 in vivo drug responses, and accompanying clinical information on the patients from which they were derived (pre and post tumor sample acquisition of drug treatments and responses, age, gender, ethnicity, tumor stage, tumor grade, location of tumor biopsy, histology, etc.) from the TumorBank. A unique feature of this proprietary dataset is its derivation from a living TumorBank, allowing for continuous characterization over time and increased depth of accumulated data. The breadth and depth of the TumorBank and its associated characterization drive the value of the Datacenter.